Adverse events ‐ All adverse events · people with inhibitors
Summary of findings table ‐ Concizumab prophylaxis showed no clear difference in adverse events ‐ All adverse events compared with on‐demand therapy (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: bronchoconstriction · children and adults with cystic fibrosis
1 finding from 1 review
Serious adverse events (6–10 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in serious adverse events (6–10 weeks) compared with placebo (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
Summary of findings table ‐ Oral small molecule inhibitors… showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Topical small molecule inhibitors… changes incidence of serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Intervention not reported
Serious adverse events up to day 45 · non‐hospitalised adults with mild COVID‐19
The intervention showed no clear difference in serious adverse events up to day 45 (low certainty).
1 finding from 1 review
Acute kidney injury · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).
1 finding from 1 review
Acute kidney injury · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).
1 finding from 1 review
Non‐serious adverse events 43 weeks · adults and children with chronic asthma
It is very uncertain whether increased changes non‐serious adverse events 43 weeks compared with stable doses of inhaled corticosteroids (very low certainty).
1 finding from 1 review
Adverse events (fistulae formation) · adults with an open abdomen after surgery who have not experienced trauma
It is very uncertain whether NPWT changes adverse events (fistulae formation) compared with the Bogota bag (very low certainty).
1 finding from 1 review
Adverse events (fistulae formation) · adults with an open abdomen after surgery who have not experienced trauma
It is very uncertain whether suprasorb CNP system changes adverse events (fistulae formation) compared with the ABThera system (very low certainty).
1 finding from 1 review
Adverse events: all grades · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab showed no clear difference in adverse events: all grade by week 8 compared with placebo (low certainty).
1 finding from 1 review